Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07270939

Optimizing Enteral Nutrition Regimen for Critically Ill Patients

Clinical Trial The goal of this clinical trial is to learn whether different enteral feeding cycles (18-hour, 20-hour, or standard 24-hour continuous feeding) improve outcomes for critically ill ICU patients who need tube feeding. It will also look at tolerance, nutrition delivery, and safety.

The main questions it aims to answer are:

Do shorter feeding cycles (with fasting windows) reduce ICU length of stay?

Do they lower the risk of infections like ventilator-associated pneumonia?

How do they affect calorie delivery, blood sugar control, and gastrointestinal tolerance?

Researchers will compare:

Continuous 24-hour feeding (standard care)

20-hour feeding with a 4-hour fasting window

18-hour feeding with a 6-hour fasting window

Participants will:

Be critically ill adults in the ICU who require at least 7 days of enteral feeding

Be randomized to one of the three feeding schedules

Receive daily monitoring of calories, protein, blood sugar, and GI tolerance

Have outcomes measured, including ICU length of stay, infections, metabolic control, and feeding tolerance

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

This randomized controlled trial will compare three enteral feeding regimens in critically ill ICU patients: standard 24-hour continuous feeding, 20-hour cycled feeding with a 4-hour fasting window, and 18-hour cycled feeding with a 6-hour fasting window. The rationale is that continuous feeding may impair metabolic regulation, increase insulin requirements, and contribute to gastrointestinal intolerance, while cycled feeding could better align with circadian rhythms, support metabolic balance, and reduce complications such as ventilator-associated pneumonia.

Approximately 150 adult patients who require enteral nutrition for at least seven days will be enrolled across Hamad Medical Corporation ICUs. Participants will be randomized in a 1:1:1 ratio using block randomization through REDCap to ensure allocation concealment. All groups will receive isocaloric enteral nutrition through nasogastric or orogastric tubes, with caloric and protein targets guided by indirect calorimetry or weight-based calculations.

Feeding plans will be initiated within 24 hours of ICU admission or stabilization. Patients assigned to the 18-hour and 20-hour arms will have structured fasting periods, while the control group will receive uninterrupted feeding. Daily assessments will capture nutritional delivery, gastrointestinal tolerance, and metabolic parameters, along with safety monitoring for adverse events. Data will be collected electronically via REDCap, de-identified, and audited regularly by the Clinical Trial Unit.

The study is designed to generate high-quality evidence on whether incorporating fasting windows into feeding schedules can optimize nutrition therapy, improve tolerance, reduce ICU stays, and minimize complications. Findings are expected to inform future ICU nutrition guidelines and contribute to the global discussion on intermittent versus continuous feeding practices.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants must meet ALL of the following criteria to be eligible for the study:

  • Patients aged ≥ 18 years.
  • Patients expected to require enteral nutrition (EN) for ≥ 7 days.
  • Critically ill, mechanically ventilated patients in the ICU.
  • New patients initiating EN in the critical care unit.
  • Patients receiving EN via:
  • a nasogastric (NG) tube.
  • orogastric (OG) feeding tube.

Exclusion criteria

  • Patients with contraindications to enteral feeding or pre-existing gastrointestinal disorders, including:
  • Active GI bleeding.
  • Progressive GI disease.
  • Recent GI tract resection.
  • Indication for a special diet formula.
  • Need for a large volume of feeding (as determined by the clinical team).
  • Pre-existing hepatic failure.
  • Use of a nasojejunal tube, gastrostomy, or jejunostomy.
  • Pregnancy confirmed via β-hCG testing for women of childbearing potential.
  • Insulin-dependent diabetes mellitus.

Treatment and study plan

20-Hour Cycled Enteral Nutrition with a 4-Hour Fasting Window

Behavioral

20-Hour Cycled Enteral Nutrition with a 4-Hour Fasting Window (Intervention 1) Objective: To evaluate the physiological benefits of a structured daily fasting period while maintaining a conservative approach to caloric delivery.

Other names: Group Intervention 1

18-Hour Cycled Enteral Nutrition with a 6-Hour Fasting Window

Behavioral

Feeding Schedule involves enteral nutrition over an 18-hour period while incorporating a 6-hour fasting window in each 24-hour cycle. This structure is designed to test a more intense intermittent fasting regimen, aiming to enhance physiological benefits by better aligning with circadian rhythms. The expectations include improved metabolic control, enhanced gastrointestinal motility, and reduced infection rates, with careful monitoring for reduced caloric intake risk. Consequently, the feeding rate is increased to meet daily caloric goals within the 18-hour timeframe, resulting in the most intensive feeding schedule among the three examined arms.

Other names: Group Intervention 2

Primary outcomes

  1. ICU Length of Stay (LOS)

    Time frame: From the date of randomization until the date of ICU discharge or transfer, assessed up to 90 days (or until hospital discharge if it occurs earlier).

    The total number of days a patient spends in the intensive care unit, calculated from the date of ICU admission to the date of discharge or transfer out of the ICU.

Secondary outcomes

  1. Nosocomial Infection/Pneumonia Incidence

    Time frame: Assessed daily from Day 3 to Day 7.

    Infections acquired after 48 hours of hospital admission, specifically including Ventilator-Associated Pneumonia (VAP). Diagnosed based on CDC criteria (clinical signs, laboratory findings, and imaging).

  2. Nutritional Adequacy

    Time frame: Calculated daily from Day 1 to Day 7

    The percentage of the prescribed daily caloric goal that is actually delivered to the patient.

  3. Gastrointestinal Complications

    Time frame: Monitored daily from Day 1 to Day 7

    Adverse events related to feeding intolerance.

  4. Gastric Emptying Index

    Time frame: Measured every 4 hours, daily from Day 1 to Day 7.

    A measure of gastrointestinal motility, indicated by delayed gastric emptying. Aspirate gastric contents via a nasogastric (NG) or orogastric (OG) tube at regular intervals (every 4 hours). gastric residual volume ≤ 500 mL, persistently high GRV (>500 mL) indicates delayed emptying.

  5. Glycemic Control

    Time frame: Daily, from Day 1 to Day 7 of the intervention.

    The regulation of blood glucose levels during the enteral nutrition intervention period.Average daily blood glucose level (mmol/L or mg/dL), calculated from point-of-care testing performed throughout the day.

  6. Insulin Requirement

    Time frame: Daily, from Day 1 to Day 7 of the intervention.

    The total daily exogenous insulin dose required to maintain blood glucose within target range.Total insulin dose administered per 24-hour period, measured in units.

  7. Serum Creatinine level, measured in mg/dL (or µmol/L)

    Time frame: Measured daily from Day 1 to Day 7. The baseline value is recorded on Day 0.

    The change in serum creatinine concentration from baseline serves as a specific biomarker of glomerular filtration rate (GFR) and kidney function.

  8. Blood Urea Nitrogen (BUN) level, measured in mg/dL (or mmol/L)

    Time frame: Measured daily from Day 1 to Day 7 of the intervention. The baseline value is recorded on Day 0.

    Change in blood urea nitrogen concentration from baseline, as a biomarker of nitrogenous waste accumulation influenced by renal function, protein catabolism, and hydration status.

  9. Alanine Aminotransferase (ALT) level, measured in U/L

    Time frame: Measured daily from Day 1 to Day 7 of the intervention. The baseline value is recorded on Day 0.

    The change in serum alanine aminotransferase (ALT) concentration from baseline serves as a specific biomarker of hepatocellular injury.

  10. Aspartate Aminotransferase (AST) level, measured in U/L

    Time frame: Measured daily from Day 1 to Day 7 of the intervention. The baseline value is recorded on Day 0.

    Change in serum aspartate aminotransferase (AST) concentration from baseline, as a biomarker of hepatic inflammation and injury.

  11. Total Bilirubin level, measured in mg/dL (or µmol/L)

    Time frame: Measured daily from Day 1 to Day 7 of the intervention. The baseline value is recorded on Day 0.

    The change in serum total bilirubin concentration from baseline serves as a biomarker of hepatic excretory function and bile flow.

Other outcomes

  1. Inflammatory Marker

    Time frame: Measured daily from Day 1 to Day 7.The baseline value is recorded on Day 0.

    Level of systemic inflammation by Inflammatory Markers (e.g., CRP)

  2. Patient Tolerance

    Time frame: Measured daily from Day 1 to Day 7

    The ability to receive enteral nutrition without significant adverse effects.

Sponsors and collaborators

Lead sponsor

Hamad Medical Corporation

Industry

Registry information

Official study title

Optimizing Enteral Nutrition: A Comparative Study of 18-Hour, 20-Hour, and 24-Hour

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2025
Registry last updated
Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.